EMA welcomes political agreement on new EU pharmaceutical legislation Reform to enhance patient access, strengthen medicine supply security and boost innovation

EMA publishes information on the volume and outcome of marketing authorisation and post-authorisation applications for the human and veterinary medicines that it evaluates.

Information on the regulation of medicines for human use in the European Union (EU), with a focus on the centralised procedure. The European Medicines Agency (EMA) plays a key role in this procedure.

Find all new and updated information published on our website in one place below. Filters are available to narrow results down based on your interests, such as whether it relates to human or veterinary …

EMA business hours over holiday period The European Medicines Agency's (EMA) office is closed from 18:00 on 22 December to 08:30 on 5 January

The European Medicines Agency (EMA) is responsible for the scientific evaluation of centralised marketing authorisation applications (MAA). Once granted by the European Commission, the …

Check EMA's annual reports for insights into our regulatory procedures, activities, and achievements. The reports include an interactive timeline and figures and statistics for easy comprehension.

While the majority of new, innovative medicines are evaluated by EMA and authorised by the European Commission in order to be marketed in the EU, most generic medicines and medicines available …

On this page you can find several ways to contact the European Medicines Agency (EMA) depending on your need for assistance or type of request.

Dec 11, 2025 · EMA welcomes the landmark political agreement reached by the European Commission, the European Parliament and the Council of the European Union on the comprehensive reform of the …